Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of JNJ-39758979 in active rheumatoid arthritis despite methotrexate
2011-002849-36Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JNJ-39758979 in rheumatoid arthritis (RA) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in DAS28 (CRP) at Week 12. Started Nov 2011; status: terminated.
02
Drugs
JNJ-39758979
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-002849-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002849-36.